Trump expected to pick Dr. Heidi Overton to lead FDA

Heidi Overton Set to Take Helm of FDA After Turbulent Transition

Goldlaner.com – Dr. Heidi Overton is poised to become the next commissioner of the US Food and Drug Administration, a move that would place a trusted White House insider at the head of one of the most politically contested federal agencies in recent memory. Two individuals familiar with the deliberations confirmed that President Donald Trump intends to nominate Overton, who currently serves as deputy director of the Domestic Policy Council. The announcement would arrive roughly three months after the departure of Dr. Marty Makary, Trump’s first FDA commissioner, who resigned under mounting pressure from the White House over disagreements on agency direction.

A Career Built at the Intersection of Medicine and Politics

Overton is a physician by training, and her professional trajectory has been shaped by repeated cycles between government service and conservative policy circles. She held a position during Trump’s first term before transitioning to the America First Policy Institute, a think tank where she ultimately directed the health policy center. That role gave her deep familiarity with the ideological currents driving the current administration’s approach to public health regulation.

Her current post at the Domestic Policy Council has placed her at the center of crafting and implementing the administration’s broader health care agenda. In that capacity, she has been involved in decisions that range from vaccine scheduling to pesticide policy — areas where the White House has at times moved in directions that diverged from earlier statements by other senior health officials.

A Confirmation Fight Looms in the Senate

Should the nomination proceed formally, Overton will face what is likely to be another contentious confirmation process before the Senate Health, Education, Labor, and Pensions Committee. The chamber’s recent history offers little comfort for a smooth path. Earlier this month, senators narrowly approved Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention, but only after Republican Sen. Bill Cassidy stalled the vote over his longstanding objections to the administration’s vaccine posture.

The friction between Cassidy and the White House intensified shortly after the CDC confirmation, when Trump signed an executive order seeking to overhaul the nation’s childhood immunization schedule. The move drew sharp criticism from Cassidy and from much of the public health establishment. Overton was present in the Oval Office, standing behind the president as he signed the order — a visual reminder of her proximity to decisions that continue to divide Congress and the medical community.

How the Search Narrowed

Health officials have been searching for a replacement FDA commissioner since Makary’s May resignation. Those who led the candidate review prioritized individuals capable of stabilizing an agency that had endured frequent leadership turnover and internal disputes over a wide range of policy questions. The pool of finalists eventually shrank to a small group, including Overton and Dr. Jeff Vacirca, a well-known cancer physician, two people familiar with the process said.

Overton’s candidacy gained decisive momentum through her close working relationship with White House chief of staff Susie Wiles and a preexisting rapport with Trump himself. Agriculture Secretary Brooke Rollins, who has collaborated closely with the Department of Health and Human Services over the past several months, was also regarded as a key supporter of Overton’s selection. Rollins and Overton had worked together during Trump’s first term and subsequently at the America First Policy Institute, giving them a shared institutional history that few other candidates could match.

Tensions Within the Administration’s Health Coalition

The selection is not without internal friction. Some figures associated with the “Make America Healthy Again” movement have expressed skepticism about Overton’s role in earlier White House decisions this year to walk back the most controversial elements of HHS Secretary Robert F. Kennedy Jr.’s agenda — particularly around vaccines — and to align with agricultural industry interests on pesticide questions.

Although Overton and Kennedy have collaborated on numerous health priorities, observers familiar with the dynamic have raised questions about how the two would function in a hierarchy where the FDA commissioner is technically subordinate to the HHS secretary. That structural tension could shape day-to-day decision-making at the agency and influence how Kennedy’s broader policy ambitions are implemented or constrained at the regulatory level.

What the Nomination Signals

The choice of Overton underscores a pattern in this administration: placing loyal insiders with direct access to the president at the helm of agencies whose mandates intersect with politically charged science and regulation. For the FDA — an agency responsible for reviewing drugs, medical devices, food safety standards, and vaccine approvals — that arrangement raises questions about institutional independence that have persisted since the agency’s founding in 1905.

The White House did not immediately respond to a request for comment on the expected nomination. Bloomberg News was the first outlet to disclose Overton’s anticipated selection. If confirmed, the nomination will set the stage for yet another high-stakes Senate battle over who controls the gatekeeping function for America’s medicines and food supply.